root cause – Page 121

Phase separation observed during transfer – CAPA failure explained

Addressing Phase Separation Issues During Transfer: A Comprehensive Investigation Guide Phase separation in ointments and creams during transfer can signify serious manufacturing defects that may compromise product integrity and patient…

Phase separation observed after packaging change – formulation vs process investigation

Investigating Phase Separation Issues Following Packaging Changes Phase separation in ointments and creams can lead to significant manufacturing defects, notably after changes in packaging. This article equips pharmaceutical professionals with…

Fill volume variability during PAI readiness – patient safety risk analysis

Analyzing Fill Volume Variability During PAI Readiness: A Comprehensive Investigation In the pharmaceutical manufacturing landscape, ensuring the accuracy of fill volumes during Pre-Approval Inspection (PAI) readiness is critical. Variability in…

Media fill failure during aseptic filling – CAPA effectiveness failure

Investigation of Media Fill Failures in Aseptic Filling: Understanding CAPA Effectiveness In the realm of pharmaceutical manufacturing, particularly when dealing with injectable products, the integrity of aseptic processes is paramount.…

CCIT failure during PAI readiness – patient safety risk analysis

Addressing CCIT Failures During PAI Readiness: A Comprehensive Investigation Approach In the high-stakes world of pharmaceutical manufacturing, ensuring the integrity of injectable products is critical. A recent issue surrounding container…

Endotoxin OOS during aseptic filling – FDA/MHRA inspection outcome

Addressing Endotoxin OOS Findings During Aseptic Filling: A Comprehensive Investigation Guide In pharmaceutical manufacturing, the detection of endotoxin presence during the aseptic filling process poses a significant challenge. Such incidents…

Particulate matter detected post-sterile filtration – patient safety risk analysis

Analyzing the Risk of Particulate Matter Detected After Sterile Filtration in Pharmaceutical Manufacturing Particulate matter detected post-sterile filtration is a significant issue in pharmaceutical manufacturing, particularly for injectable products. The…

Endotoxin OOS during PAI readiness – CAPA effectiveness failure

Examining Endotoxin OOS Events During PAI Readiness: Strategies for Effective CAPA In the highly regulated pharmaceutical industry, the incidence of out-of-specification (OOS) results, particularly concerning endotoxins during the pre-approval inspection…

Endotoxin OOS during stability testing – CAPA effectiveness failure

Addressing Endotoxin OOS During Stability Testing: Effective Investigation and CAPA Strategies Discovering an endotoxin Out of Specification (OOS) result during stability testing can significantly impact product quality and compliance. This…

Fill volume variability during aseptic filling – FDA/MHRA inspection outcome

Addressing Fill Volume Variability in Aseptic Filling: An Investigation Framework Fill volume variability during aseptic filling is a challenging issue that can lead to regulatory scrutiny and compromised product quality.…

CCIT failure post-sterile filtration – FDA/MHRA inspection outcome

Investigating CCIT Failure After Sterile Filtration: Regulatory Insights Contamination Control Integrity Testing (CCIT) failures occurring post-sterile filtration pose significant challenges in pharmaceutical manufacturing. Such failures can jeopardize product sterility, leading…

Particulate matter detected during aseptic filling – CAPA effectiveness failure

Addressing the Detection of Particulate Matter During Aseptic Filling: An Investigation Approach Detecting particulate matter during aseptic filling can severely impact product quality, compliance, and overall operational integrity in pharmaceutical…